ADCT Long Call Strategy
ADCT (ADC Therapeutics S.A.), in the Healthcare sector, (Biotechnology industry), listed on NYSE.
ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-ineligible patients with relapsed or refractory DLBCL; and a Phase I trial for relapsed or refractory non-Hodgkin lymphoma (NHL). The company's pipeline also includes camidanlumab tesirine, another ADC, which has completed Phase I development for relapsed or refractory NHL. It is additionally progressing through Phase II for relapsed or refractory Hodgkin lymphoma and Phase Ib for selected advanced solid tumors. Furthermore, ADC Therapeutics is advancing ADCT-602, currently in Phase Ia for acute lymphoblastic leukemia, alongside ADCT-601 and ADCT-901, both of which are in Phase Ia for various solid tumors. Its preclinical portfolio features ADCT-701 and ADCT-901, both aimed at solid tumors.
ADCT (ADC Therapeutics S.A.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $156.4M, a beta of 1.84 versus the broader market, a 52-week range of 0.78-4.98, average daily share volume of 1.6M, a public-listing history dating back to 2020, approximately 191 full-time employees. These structural characteristics shape how ADCT stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.84 indicates ADCT has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a long call on ADCT?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
ADCT snapshot
As of August 14, 2026, spot at $1.02, ATM IV 26.50%, IV rank 3.12%, expected move 7.60%. The long call on ADCT below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this long call structure on ADCT specifically: ADCT IV at 26.50% is on the cheap side of its 1-year range, which favors premium-buying structures like a ADCT long call, with a market-implied 1-standard-deviation move of approximately 7.60% (roughly $0.08 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ADCT expiries trade a higher absolute premium for lower per-day decay. Position sizing on ADCT should anchor to the underlying notional of $1.02 per share and to the trader's directional view on ADCT stock.
ADCT long call setup
The ADCT long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ADCT at $1.02 on that close, the first option leg uses a $1.02 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ADCT chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ADCT shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $1.02 | N/A |
ADCT long call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
ADCT long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on ADCT. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use long call on ADCT
Long calls on ADCT express a bullish thesis with defined risk; traders use them ahead of ADCT catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
ADCT thesis for this long call
The market-implied 1-standard-deviation range for ADCT extends from approximately $0.94 on the downside to $1.10 on the upside. A ADCT long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current ADCT IV rank near 3.12% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ADCT at 26.50%. As a Healthcare name, ADCT options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ADCT-specific events.
ADCT long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ADCT positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ADCT alongside the broader basket even when ADCT-specific fundamentals are unchanged. Long-premium structures like a long call on ADCT are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current ADCT chain quotes before placing a trade.
Frequently asked questions
- What is a long call on ADCT?
- A long call on ADCT is the long call strategy applied to ADCT (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With ADCT stock at $1.02 on the most recent close, the strikes shown on this page are snapped to the nearest listed ADCT chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are ADCT long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the ADCT long call priced from the end-of-day chain at a 30-day expiry (ATM IV 26.50%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ADCT long call?
- The breakeven for the ADCT long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The ADCT market-implied 1-standard-deviation expected move in the same options snapshot is approximately 7.60%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on ADCT?
- Long calls on ADCT express a bullish thesis with defined risk; traders use them ahead of ADCT catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current ADCT implied volatility affect this long call?
- ADCT ATM IV is at 26.50% with IV rank near 3.12%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.